FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma

PARIS and TARRYTOWN, N.Y., Oct. 19, 2018 /PRNewswire/ -- Sanofi (EURONEXT: SAN) (NYSE: SNY) The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news